{"id":"NCT00593606","sponsor":"UCB Pharma","briefTitle":"Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine","officialTitle":"A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2008-01-15","resultsPosted":"2009-05-27","lastUpdate":"2014-10-02"},"enrollment":124,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":["Neupro"]}],"arms":[{"label":"Rotigotine","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease","primaryOutcome":{"measure":"Change in Pulse Rate (Supine, After 1 Minute)","timeFrame":"Baseline, 28 days","effectByArm":[{"arm":"Rotigotine","deltaMin":2,"sd":9.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":8,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21831297"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":116},"commonTop":["Dizziness","Tremor","Asthenia","Dyskinesia","Muscle rigidity"]}}